Company Description
Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally.
It offers products, such as IAM-1363, a selective HER2 inhibitor; IAM-K1, a KIF18A inhibitor; IAM217 (a KIF18A inhibitor) and IAM-C1, a CDK2/4 inhibitor; and services, including drug discovery platform and molecular superintelligence platform which includes technologies, such as Enchant and NeuralPLexer to design and develop small molecule therapeutics.
Iambic Therapeutics, Inc. was formerly known as Entos, Inc. and changed its name to Iambic Therapeutics, Inc. in May 2023.
The company was incorporated in 2019 and is based in San Diego, California.
| Country | United States |
| Founded | 2019 |
| IPO Date | Oct 15, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 171 |
| CEO | Thomas Miller |
Contact Details
Address: 5627 Oberlin Drive, Suite 120 San Diego, California 92121 United States | |
| Phone | (619) 330-5499 |
| Website | iambic.ai |
Stock Details
| Ticker Symbol | IAM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 1997038 |
| CUSIP Number | 45076A101 |
| ISIN Number | US45076A1016 |
| Employer ID | 84-3364168 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Thomas Miller, Ph.D. | Chief Executive Officer and Director |
| Frederick Manby, Ph.D. | Chief Technology Officer and Director |
| Neil Josephson, M.D. | Chief Medical Officer |
| Peter Olson, Ph.D. | Chief Scientific Officer |
| Michael Secora, Ph.D. | Chief Financial Officer and Chief Corporate Development Officer |
| Samit Hirawat, M.D. | Director |
| Evan Rachlin, M.D. | Director |
| William Rastetter, Ph.D. | Director |
| Shalini Sharp | Director |
| Mary Tagliaferri, M.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 16, 2026 | 8-K | Current Report |
| Oct 15, 2026 | 424B4 | Prospectus |
| Oct 15, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Oct 14, 2026 | EFFECT | Notice of Effectiveness |
| Oct 14, 2026 | CERT | Certification by an exchange approving securities for listing |
| Oct 13, 2026 | 8-A12B | Registration of securities |
| Oct 8, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Sep 21, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Sep 9, 2026 | D | Notice of Exempt Offering of Securities |
| Aug 28, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |